logo-loader
viewAchieve Life Sciences Inc

Achieve Life Sciences to begin Phase 2b trial for its smoking cessation drug

The data results of the study are expected to be made available in mid-2019

A put out cigarette
Its drug interacts with the brain’s nicotine receptors to reduce nicotine withdrawal symptoms

Achieve Life Sciences Inc (NASDAQ:ACHV) shares soared double digits following the announcement that it will begin its Phase 2b trial for Cytisinicline, its smoking cessation drug.

Known as its Ongoing Research of Cytisinicline for Addiction Program, or ORCA, the trial will evaluate the effectiveness of the drug on smoking cessation.

READ: Achieve Life Sciences shares climb following positive results from its smoking cessation study

Shares of the Washington State-based biotech jumped more than 20% to $2.52 in Tuesday Morning trading.

The randomized study will look at 1.5mg and 3mg  doses of cytisinicline over 25 days, as well as three times daily dosing.

The plant-based compound, also known as cytisine, interacts with the brain’s nicotine receptors to reduce nicotine withdrawal symptoms.

The effectiveness of the trial will be determined by the reduction in the number of cigarettes smoked during treatment.

A total of 250 smokers will participate in a study being conducted across eight US centers.

“We intend to utilize our learnings from this trial to finalize the Phase 3 program, expected to begin later next year,”  said CEO Rick Stewart in the company’s press release.

The data results are expected to be made available in mid-2019.

The company also announced that the United States Adopted Names Council adopted "cytisinicline" as the generic name for cytisine.

 

Contact Lenore Fedow at [email protected]

Follow her on Twitter@LenoreMariee

 

Quick facts: Achieve Life Sciences Inc

Price: 0.497 USD

NASDAQ:ACHV
Market: NASDAQ
Market Cap: $12.44 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Sativa Group signs significant product listing with WH Smith...

Sativa Group (Nex: SATI) CEO Henry Lees-Buckley dropped into the Vancouver studio of Proactive with news the company has signed a major CBD product listing agreement with WH Smith Travel.  Lees-Buckley talks about just how big that deal is and what he has been hearing from customers...

10 hours, 23 minutes ago

2 min read